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EXECUTIVE SUMMARY
According to the Pakistan Demographic and Health Survey (PDHS) 2006‐07, the maternal mortality ratio
for Pakistan is reported at 276 per 100,000 live births (NIPS and Macro International, 2008). In rural
areas, this figure is 319 per 100,000 live births. The PDHS 2006‐07 also showed that postpartum
hemorrhage was the most common cause of maternal deaths (27.2 percent). Around two‐thirds of all
births in Pakistan take place at home, where a traditional birth attendant (TBA or dai) or a family
member usually attends the delivery (NIPS and Macro International, 2008). In Pakistan, owing to limited
access to health facilities, about 61 percent of deliveries are conducted by unskilled birth attendants
within home settings.
This operations research project was carried out by the Population Council as part of the Pakistan
Initiative for Mothers and Newborns (PAIMAN) project funded by the United States Agency for
International Development (USAID). The overall goal of the project was to test the feasibility of
administering misoprostol for the prevention of PPH in a home setting through community‐based
healthcare providers, including traditional birth attendants (dais), or family members, in two districts of
Pakistan.
The study was conducted to document the feasibility of distribution of misoprostol by community health
workers in a home setting and to assess the acceptability and use of the drug by pregnant women for
the prevention of PPH when administered at home. Besides this, to identify the common side effects of
misoprostol and determine the reduction in demand for referral due to PPH after oral ingestion of
misoprostol.

Study Design/Methodology
This operations research (OR) was conducted in Dadu district, Sindh province, and Khanewal district,
Punjab province. The quasi‐experimental design used for this study comprised of intervention and
comparison areas. Data collection was carried out from November 2009 to June 2010 using a number of
data collection tools.
The study consisted of two phases: the first phase involved community awareness and community
education, through counseling, and the second involved data collection. During community awareness
and registration of the women, each identified pregnant woman and her family members, in the
comparison and intervention areas, were given a briefing about birth preparedness and danger signs
during pregnancy, delivery and the postpartum period. For women in the intervention areas, the
briefing also included information about misoprostol. For all identified pregnant women, these initial
briefings were designed to help them make a well‐informed decision about whether to participate in the
study or not.
Later, two counseling sessions were held with the eligible pregnant women from the intervention and
comparison areas who participated in the study. The first session was conducted one month before each
ix

woman’s expected delivery date and the second was 15 days before delivery. Information on the same
topics that had been touched on in the initial briefings was presented during each of the counseling
sessions/visits. During the second visit, clean delivery kits were given to the women in both areas. The
clean delivery kits for the women in the intervention areas contained three tablets of 200 micrograms of
misoprostol each, along with a pictorial instructional leaflet. For this research, VSI Venture Strategies
Innovations donated 6,000 misoprostol tablets. The clean delivery kits given to the women in the
comparison areas did not include misoprostol tablets.
The 566 birth attendants identified by the pregnant women as the people expected to carry out their
deliveries were given a one‐day interactive training. Each person identified as an expected birth
attendant, whether a TBA or a family member, was also given a clean delivery kit (with misoprostol in
the intervention areas and without misoprostol in the comparison areas).

Results
Characteristics of the Women
Out of a sample of 872 women in the intervention areas and 826 women in the comparison areas who
had initially agreed to participate in the study, the mean age in both areas was 28 years. Mean
education in the intervention areas was 1.7 years; it was 1.3 years in the comparison areas. The mean
number of live births was 3.0 in the intervention areas and 2.8 in the comparison areas. Nearly half of
the respondents in both areas had made at least one antenatal visit. More than two‐fifths of the
husbands, in both intervention and comparison areas, were uneducated (41 and 47 percent
respectively).

Characteristics of the Birth Attendants
About 80 percent of the birth attendants in both the intervention and comparison areas were traditional
birth attendants/dais. MBBS doctors made up the second largest group of attendants: 6 percent in the
intervention areas and 10 percent in the comparison areas. More than half of the birth attendants in
both areas were 45‐64 years of age, fairly evenly split between 45‐54 and 55‐64. Just over 70 percent of
the birth attendants in both areas were uneducated, as most were traditional birth attendants (TBAs). A
major proportion of birth attendants were currently married: 65 percent ‐ intervention areas; 58
percent ‐ comparison areas. Widows were the second most common group in both areas; very few birth
attendants were single or separated.

Knowledge of Respondents
Women in the intervention areas were provided a briefing on misoprostol’s advantages and use during
the initial community awareness and registration session. When the study participants were interviewed
one month before their expected delivery date to ascertain how much of the information they had
retained, 95 percent of the women in the intervention areas mentioned that tablets taken orally could
prevent PPH. About 52 percent of these women were able to recall that the name of the drug was
misoprostol. Among those who knew about misoprostol, 92 percent knew how to use it correctly.
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Knowledge of Birth Attendants
Almost all of the birth attendants in both intervention and comparison areas (around 95 percent) knew
how to recognize postpartum hemorrhage. Over half of the birth attendants (60 percent) could recall
the name of the tablets (misoprostol). Almost all (98 percent) of the birth attendants knew, correctly,
that misoprostol should be administered immediately after delivery of the baby and before delivery of
the placenta. About 78 percent of the birth attendants knew that shivering is one of the side effects of
misoprostol and 67 percent knew about fever, while smaller percentages knew about other side effects.

Misoprostol Use: Safety, Acceptability and Referral
Safety
Out of the 890 women identified in the intervention areas as pregnant, 872 agreed to participate in the
study, while 18 refused. Out of 872 who agreed to participate, 770 delivered at home and were eligible
for misoprostol. Among the remaining, 55 were ineligible because a cesarean section delivery was
indicated, and 47 were excluded due to referral to facility before delivery for obstetric complications.
Among the eligible women in the intervention areas, 678 women (88 percent) took the misoprostol
tablets provided to them in the clean delivery kits, while 92 women (12 percent) did not.
In the comparison areas, 826 agreed to participate and 720 with home deliveries were included. Out of
the other 106 women, 77 with a history of C‐sections were deemed ineligible for inclusion in the study,
and 29 were referred to a facility for other obstetric complications and were also excluded from the
analysis.
The recommended time and dosage of misoprostol administration is three tablets to be ingested after
the birth of the baby but prior to the delivery of the placenta. Of the women who delivered at home in
the intervention areas, 647 (84 percent) took the tablets correctly (at the correct time and according to
the correct dose).
The 647 women who took misoprostol tablets correctly (correct dose and correct time) were asked
about the side effects and 40 percent reported that they had experienced side effects (Table 4.2). The
majority reported suffering shivering/chills (69 percent), followed by fever (27 percent) and nausea (17
percent). However, in all of these cases, the symptoms were transient and did not require referral for
specialized care.
Acceptability
Women who used misoprostol. Among the women who delivered at home and used misoprostol, 91
percent said that they would use the tablets in future. When these women were asked if they would
also be willing to purchase the tablets in the future, 93 percent expressed their willingness to do so.
Almost all of these women also said they would recommend misoprostol to others (only 2 were not
willing to recommend misoprostol).
Birth attendants. Of those birth attendants in the intervention areas who had administered misoprostol
tablets and knew of its name (nearly 60 percent), almost all (98 percent) said that they would
recommend the tablets to other clients.
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Referral
In the intervention areas, 3 women (0.38 percent) suffered from postpartum hemorrhage that required
referral to a higher‐level facility. Out of these, 2 had ingested misoprostol; the 1 who had not ingested
misoprostol later died upon reaching a facility. In the comparison areas, 5 (0.64 percent) required
referral for the management of PPH; out of these cases, two women died.

Recommendations
•

Train community based providers in the use of misoprostol in resource constrained settings
The results from our study further substantiate the already available empirical evidence that
recommends the use of misoprostol in resource‐constrained settings by community providers. For
this purpose training needs to be imparted to LHW’s and community midwives in the use of
misoprostol including its dosage, side effects and their management.

•

Empower families to make pregnancies safer through information
Raising community awareness regarding the need for birth spacing, antenatal checkups, proper
nutrition during pregnancy, use of supplements, immunization, use of clean delivery kits at the time
of delivery, and postpartum use of misoprostol must be carried out, especially in rural communities.
In this regard LHWs through their support group meetings can especially raise awareness regarding
use of misoprostol by delivering women and their birth attendants.
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CHAPTER 1. INTRODUCTION
Background
Globally, about 500,000 women die annually from complications during pregnancy or childbirth (WHO,
2004). The most common cause of maternal mortality is postpartum hemorrhage, accounting for one‐
third of maternal deaths. Ninety‐nine percent of these deaths occur in developing countries to women
who rarely receive appropriate care because they give birth outside of a hospital setting (Abou Zhar and
Royston, 1991).
Postpartum hemorrhage (PPH) is widely defined as excessive blood loss of 500 ml or more from the
genital tract in the first 24 hours following delivery of a baby. In the majority of cases, PPH occurs in the
early postpartum period. Vaginal tears, retained products of placenta, and delayed delivery of placenta
and uterine atony (which delays placental detachment and eventually its delivery) are the major factors
that contribute to the incidence of PPH. Three effective uterotonic drugs are available for use in the
active management of the third stage of labor.
As a routine, the injectable oxytocin is recommended at the time of delivery of a baby to prevent PPH. It
acts as a uterotonic and facilitates the process of placenta detachment as well as contraction of the
uterus. Oxytocin has minor adverse effects, including nausea, vomiting and diarrhea. It requires storage
in a cool temperature (5‐25°C), although it can be kept outside these temperatures for short durations.
The other drug is methergin. Adverse effects with methergin are more common; it is also less stable in
warm temperatures, requires dark storage, and cannot be used in the 10 to 15 percent of women who
have hypertension in pregnancy. Both of these drugs require a skilled provider trained in safe injection
practices and they require the availability of sterile syringes and needles (Sanghvi et al., 2010).
Misoprostol, a prostaglandin E1, acts as an alternative uterotonic to the injectable drug oxytocin and is
available in tablet form. It has been found to be effective in controlling as well as preventing PPH (Prata,
Mbaruku, Campbell, Potts, Vahidnia, 2005; Derman et al., 2006). It is inexpensive, comparatively easy to
use, and does not require any special conditions for its storage. Moreover, its tablet form provides a
community health care provider, a traditional birth attendant, and even the just‐delivered woman
herself, with the opportunity to easily administer it. Misoprostol causes occasional side effects, which
include shivering and fever (Derman et al., 2006; Zuberi et al., 2008; Blum, Alfirevenic, Walraven, Weck,
Winikoff, 2007; Sultana and Khatun, 2007). The use of misoprostol has been recommended by the
United States Pharmacopoeia (USP) Expert Committee for the Prevention of PPH, especially in settings
where injectable uterotonic drugs are not available (Carpenter, 2001).
According to the Pakistan Demographic and Health Survey (PDHS) 2006‐07, the maternal mortality ratio
(MMR) for Pakistan is reported at 276 per 100,000 live births (NIPS and Macro International, 2008). In
rural areas, this figure is 319 per 100,000 live births. The PDHS 2006‐07 also showed that postpartum
hemorrhage was the most common cause of maternal deaths (27.2 percent).
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The purpose of the present study was to test the feasibility of lowering maternal mortality using
community education about PPH prevention along with the distribution of misoprostol tablets directly
to women and their birth attendants for postpartum home administration. According to the PDHS,
around two‐thirds of all births in Pakistan take place at home, where a traditional birth attendant (TBA
or dai) or a family member usually attends the delivery (NIPS and Macro International, 2008). In these
circumstances, providing women with 600 micrograms of misoprostol, taken orally, is a potentially safe
and easy way to prevent the development of PPH in resource‐constrained settings without appropriate
storage facilities or highly trained providers (Derman et al., 2006).

Context
Before commencing this study, an extensive review of international and national literature was carried
out to inform the study design. Some of the main findings relevant to the study are summarized below.
The leading cause of postpartum hemorrhage is uterine atony, most often preventable by conventional
uterotonics, among which oxytocin is usually preferred (Gülmezoglu et al., 2001; Langenbach, 2006; Ng
et al., 2001). However, the use of oxytocin is not yet feasible in much of the developing world, where
deliveries still take place in rural areas with untrained birth attendants (Langenbach, 2006; Selo‐Ojeme,
2002; Kodkany et al., 2004; Walraven et al., 2005).
The role of misoprostol in preventing PPH, particularly in areas where the routine management of the
third stage of labor cannot be practiced, has been very well established. Research on misoprostol has
been carried out either as randomized controlled trials or operations research in some developing
countries with promising results for the management of PPH (Derman et al., 2006; Prata, Hamza,
Gypson and Nada, 2006; Prata et al., 2005). Evidence from many developing countries is now available
regarding the successful distribution of misoprostol, its acceptability in the community after proper
creation of awareness, and compliance by pregnant women and support from their families.
A review carried out by Goldberg, Greenberg and Darney (2001) found consistent evidence to support
the use of misoprostol for preventing PPH in circumstances where oxytocin is not available. A study of
education and home‐based distribution of misoprostol for prevention of PPH carried out in neighboring
Afghanistan showed that the distribution of misoprostol by community health workers was safe,
acceptable, feasible and effective (Sanghvi et al., 2010). Derman et al. (2006) conducted a placebo‐
controlled trial in India that utilized the services of nurses and midwives to give 600 micrograms of
misoprostol orally. This study documented a significant decrease in PPH in the intervention group as
compared to the comparison group. Prata et al. (2005) conducted a field intervention trial in Tanzania
with TBAs where they gave 1000 micrograms of misoprostol rectally at the onset of PPH. The study
found this resulted in lower referrals for PPH to higher‐level health facilities as compared to the non‐
intervention areas. The same researchers carried out another study in a hospital setting in Egypt where
a significantly higher proportion of women in the non‐intervention group required PPH management as
compared to the intervention group that received misoprostol (Prata et al., 2006). In a study carried out
in Nigeria oral misoprostol was seen to be as effective and safe as intramuscular oxytocin (Afolabi, Kuti,
Orji and Ogunniyi, 2010).
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Introduction

JHPIEGO conducted a community‐based study in collaboration with the Ministry of Health of Indonesia
and the Obstetrical and Gynaecological Society of Indonesia in 2004. The study was developed to
demonstrate that community‐based distribution of 600 micrograms of misoprostol before delivery of a
baby and the self‐administration of the drug by the mother immediately after a home birth could lower
the incidence of PPH among women living in areas where skilled providers do not attend a high
proportion of births. In the intervention areas, 93.7 percent of 1,282 women used the drug after
delivery. Nearly 4 percent of the women in the comparison areas were referred for PPH compared to
only 2.1 percent of women in the intervention areas. The authors used statistical models in the data
analysis to conclude that women in the intervention areas were 25 percent less likely to experience
excessive bleeding, 30 percent less likely to need an emergency referral to a health facility, and 45
percent less likely to need an emergency referral for PPH (Wiknjosastro and Sanghvi, 2004).
In Pakistan, two research studies on misoprostol use, conducted in hospital and community settings,
have been documented. Both were carried out by Aga Khan University. The first study was a hospital‐
based treatment‐placebo‐control trial in which 600 micrograms of misoprostol were given sublingually
with the routine management of PPH treatment (Zuberi et al., 2008). The results were modestly in
support of misoprostol use, but there were no statistically significant differences between the
intervention (oxytocin and misoprostol) and comparison (oxytocin only) groups. However, the trial had
to be terminated as the PPH rate was low. Another community‐based placebo‐controlled trial was
conducted in Chitral in the Northern Areas where TBAs were utilized to provide 600 micrograms of
misoprostol orally to women shortly after they gave birth. The results showed that oral misoprostol
reduced the rate of PPH by 24 percent compared with the placebo. Referrals for higher‐level care during
the immediate postpartum period were similar following administration of misoprostol (2.4 percent) or
placebo (1.8 percent) (Gynuity Health Projects, Aga Khan University and Family Care International,
2009).
WHO recommends the use of misoprostol only in circumstances where use of injectables, including
oxytocin, is not possible and health workers are properly trained in the correct use of misoprostol as
well as identification and management of side effects (WHO, 2009).
The Population Council, as a consortium partner of the USAID‐sponsored Pakistan Initiative for Mothers
and Newborns (PAIMAN), undertook an operations research project in two districts of Pakistan to assess
the feasibility of home administration of misoprostol in the prevention of PPH in rural Pakistan. The
purpose of undertaking the study was based on the premise that such an intervention has the potential
to significantly reduce the number of preventable maternal deaths and provide a powerful model for
more effective safe motherhood interventions in rural areas. This study was conducted with the
approval of the Ministry of Health (MOH) and the National Maternal, Neonatal and Child Health (MNCH)
program.

Goal and Objectives
Goal
The overall goal of this operations research project was to assess the feasibility of administering
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misoprostol for the prevention of PPH in a home setting through community‐based healthcare
providers, including traditional birth attendants (dais), community midwives (CMWs) and family
members, in two districts of Pakistan.

Objectives
The following were the objectives for this study:
•

To document the feasibility of distribution of misoprostol by community health workers,
including traditional birth attendants (dais), in a home setting;

•

To assess the acceptability and use of the drug by pregnant women for the prevention of PPH
when administered at home;

•

To identify the common side effects of misoprostol; and

•

To determine the reduction in demand for referral due to PPH after oral ingestion of
misoprostol.

Study Parameters
A quasi‐experimental design was used to document the coverage and process of distribution and the
acceptability of providing misoprostol to prevent postpartum hemorrhage in community settings in
Pakistan. The study documented the use of misoprostol by community‐based birth attendants, including
traditional birth attendants (dais); the acceptability and compliance by delivering women; and the
incidence of side effects and need for referral with the use of 600 micrograms (3 tablets) of oral
misoprostol.

Location and Duration
This was a one‐year project; it started on 27 October 2009 and ended on 30 September 2010. This study
was conducted in two districts, Dadu district in Sindh province and Khanewal district in Punjab province.
Both districts were chosen because they were focus districts of the Pakistan Initiative for Mothers and
Newborns Health (PAIMAN) project and were approved by the Technical Advisory Group (TAG)
constituted to advise on the study design. In addition, these two districts are fairly representative of the
other districts of the provinces. The characteristics of both districts are provided in Annex.
In Khanewal district, seven union councils were selected, while in Dadu six union councils were selected.
The union council selection was based on ensuring that women from both the intervention and
comparison areas could reach a referral facility within two hours of travel time.

Population
Sample Selection: Inclusion Criteria
Pregnant women living in the selected union councils of Khanewal and Dadu districts who were 15‐49
years of age and intended to deliver at home, were willing to participate in the study, and would be
delivering during the study period were included in the study. During the initial registration, women who
fit the criteria were included regardless of parity, past obstetric history or medical conditions. Also
4
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included were the birth attendants who were expected to be present at the time of delivery and to
conduct the delivery (this included TBAs, relatives, etc.).
Selection criteria of eligible pregnant women varied in different villages depending on when registration
occurred: where registration started in the beginning of the study, women in their second and third
trimesters were included, while in villages where registration was done later in the study, women only in
their third trimester were included. See Figure 1.1 and Table 1.1 for more details on study participants.
Sample Selection: Exclusion Criteria
Pregnant women in the selected union councils were excluded from the study for any of these reasons:
if they intended to deliver at a health facility, were not within the age limit of 15‐49 years, or were not
willing to participate in the study. In the final analysis of study findings, women were also excluded if
they had certain complications or previous history of complications, such as previous antepartum or
postpartum hemorrhage or retained placenta, or if they had a previous or planned Cesarean section.
Sampling Technique
Six union councils in Dadu and seven in Khanewal closest to the selected health facilities (within two
hours distance from the referral health facility) were included in the study to register the required
number of eligible women. The selected health facilities were the Tehsil Headquarters Hospital of Mian
Channu in Khanewal district and the District Headquarters Hospital of Dadu in Dadu district (both of
which offered comprehensive EmONC services). Out of these union councils, 3 in each district were
initially assigned for the intervention and 3 were assigned for the comparison. The selection of union
councils was purposive so as to avoid diffusion among the intervention and comparison areas. An
additional union council was included in the intervention areas in Khanewal district to register the
required number of eligible pregnant women, bringing the intervention areas total of union councils to 4
in Khanewal and 3 in Dadu. Registration of women was done beyond sample size to compensate for
subsequent ineligibility of some respondents.
Sample Size/Sample Size Estimation. Currently, the PPH rate is estimated to be in the range of 10‐15
percent for rural settings in countries like Pakistan (WHO, 2004), and we expected that this rate could be
reduced by half (5‐7 percent) with the introduction of misoprostol. Based on these estimates, we
calculated sample sizes on the assumption that half of the women with PPH (7 percent) would be
referred to a health facility in the comparison areas, while in the intervention areas the referrals due to
PPH would be reduced to a quarter (3.25 percent). For this purpose, a minimum of 554 deliveries in each
of the two groups was required to test the difference of a reduction of 50 percent in reported PPH
(Rosner, 1995).
The formula used for sample size estimation is:
n= (A+B) 2 *[(p1*(1‐p1)) + (p2*(1‐p2))]/ [p1‐p2]2
Where

p1=proportion of referrals due to PPH in comparison group=0.075
p2= proportion of referrals due to PPH in intervention group= 0.035
A = zα/2= 1.96 (for α= 0.05 for 95% confidence interval)
B = z 1‐β = 1.64 (for β = 0.05 for 95% power)
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A minimum of 800 pregnant women in the intervention areas and an equal number in the comparison
areas had to be enrolled in order to achieve the minimum required number of completed observations
to detect differences with public health significance. By inflating the sample size by 25 percent in the
intervention group and the comparison group, we hoped to compensate for non‐compliance in the
intervention group and hospital deliveries in both groups. Loss to follow‐up was also estimated to be
about 15 percent, thus increasing the minimum sample further. Out of 890 pregnant women initially
contacted in the intervention areas, 18 (2 percent) refused to participate in the study. Of the 846
contacted in the comparison areas, 20 (2 percent) refused to participate. See Figure 1.1, which shows
the profile of the pregnant women in the study, and Table 1.1, which shows the number completing
specified questionnaires in the intervention and the comparison areas.
Figure 1.1: Study profile of pregnant women in Dadu and Khanewal districts
1,736
Pregnant women identified

INTERVENTION
890
Pregnant women assigned for intervention

872
Agreed to
participate

18
Refused to
participate

COMPARISON
846
Pregnant women assigned for comparison

20
Refused to
participate

77
Identified for C‐sections
(ineligible)

55
Identified for C‐sections
(ineligible)

47 referrals before
delivery (excluded)

770 eligible women
(Home deliveries)
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826
Agreed to
participate

720 eligible
women
(Home deliveries)

29 referrals before
delivery (excluded)
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Study Teams
A total of eight teams were selected for fieldwork in Khanewal and Dadu districts: four teams worked in
each of the two districts. In Khanewal, 2 teams covered the 4 intervention areas and 2 teams covered
the 3 comparison areas. In Dadu, 2 teams covered the 3 intervention areas and 2 teams covered the 3
comparison areas. The study teams made three separate visits to the homes of eligible women in the
areas they were responsible for and also organized trainings for the birth attendants. Each team
comprised of one logistics supervisor and two social scientists. A female medical doctor was selected as
a district supervisor for each of the two districts.
Roles and Responsibilities
Roles and responsibilities for each study member were identified and they were provided with a written
list of responsibilities they were required to follow.
Training
A total of 16 social scientists, 8 logistics supervisors and 2 district supervisors from Khanewal and Dadu
districts were trained in Islamabad in two training sessions. The first session lasted for 10 days, the
second for 8 days.
During the first phase of the training, participants were trained on interviewing pregnant women and
then registering those who met the criteria. The second phase of the training focused on interviews to
be conducted in the postpartum period with the women, their birth attendants and relatives. During the
training, the social scientists were trained to use a pictorial booklet that informed participants about
how to identify high‐risk conditions and manage the delivery, including when to refer and, finally, how
to administer misoprostol tablets (this last was for those participants who were in the intervention areas
only).
During the training, the 8 logistics supervisors were also trained on how to establish a mobile network
for timely referral of emergency cases to the health facility.
Supervision and Monitoring
All of the teams for both districts carried out their field activities in continuous and close supervision by
their respective district supervisors (the female doctor appointed to provide supervision in each district).
The study coordinator regularly visited the study sites to ensure that sampling procedures and standard
operating procedures were being followed.
Quality Assurance
A number of measures were instituted to ensure that the highest quality standards were maintained in
all areas of the study, including data collection and data analysis. Quality assurance during the fieldwork
is described above under supervision and monitoring of field teams. The highest standards were also
maintained with regard to the protection of all study participants. These are described under ethical
considerations below.
Ethical Considerations
Ethical approval was taken from the institutional review board at the Population Council’s headquarters
in New York (see Annex, IRB Approval Letter). In addition, a Technical Advisory Group was formed that
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was comprised of representatives of the Pakistan Ministry of Health, the National MNCH Program,
academics, researchers and gynecologists. The National MNCH program, Government of Pakistan, also
issued a letter in support of the use of misoprostol for operations research. Ethical issues were taken
into considerations in all areas of the study. Specific areas for which ethical considerations were
essential included:
1. Informed consent
Informed consent was taken from all study participants in both intervention and comparison
areas after giving them information about the study (see Annex, Informed Consent Form). The
possible side effects of oral ingestion of misoprostol were discussed with the participants in the
intervention areas. Separate consent forms were used for each of the questionnaires. Women
who were able to sign signed their own names on the consent forms; if a woman could not sign
her own name, a witness present at the occasion signed the consent form on the woman’s
behalf.
2. Risks and benefits
Respondents were informed about the potential risks and benefits of participating in the study.
The individual benefits of participating in the study were explained: namely, that any woman
who developed complications at the time of delivery would be facilitated by the project team
working in that area for transportation to the health facility. In addition, all of the pregnant
women in the study, in intervention and comparison areas, were provided with clean delivery
kits for safe delivery. The potential risks of participation in the study were also explained, these
were linked to improper timing of taking the drug or not following the recommended dosage.
3. Confidentiality
The data collected from all of the study participants was kept confidential and anonymous.
Before data collection, participants were assured by the social scientists that their names would
not be disclosed and that information provided by them would be used collectively. Each
questionnaire was coded and names were not used.

Safety Measures
Safety Reporting
1. Referral cards
All households with recruited women, in both the intervention and comparison areas, were
issued referral cards with contact numbers for the logistics supervisor, drivers engaged for
transportation, birth attendants and LHV working in that particular area so that the women
could contact anyone in the network to report any side effects or complications. They were also
provided information about the importance of the first 1‐2 hours after delivery, when timely
referral in case of postpartum hemorrhage can save a life.
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2. Serious adverse event report
Any serious adverse event experienced, regardless of causality, by any subject entered into this
study, was to be reported to the Population Council’s serious adverse event (SAE) desk (by the
district supervisor) and to the Population Council’s study coordinator using the SAE form
provided. This report was to be submitted no more than 2 calendar days from the time the site
staff was notified of the event.
Safety Management
1. LHVs for back‐up support
LHVs in the study union councils were trained for back‐up support to ensure timely referral to
the health facility in case complications occurred at the time of delivery or after delivery.
2. Mobile network
A mobile phone and transportation network was established between households, logistics
supervisors and drivers for timely transportation of recruited women to the referral health
facility in case of complications at the time of delivery or after delivery.
3. Twenty‐four hour emergency services at the referral health facility
Medical officers working in obstetrics and gynecology with trained paramedics were on call 24
hours at the referral health facility. The referral facility selected in Khanewal district was the
THQ Mian Channu and in Dadu district it was the DHQ Dadu. These facilities were selected on
the basis of availability of comprehensive EmONC services.

Community Awareness and Community Education
The first phase of the study involved community awareness and community education. Preliminary
household listing was carried out in both the intervention and comparison areas, and 1,736 pregnant
women were initially identified. The listing process was facilitated by local lady health workers who
helped introduce the social scientists to household members. All pregnant women in the selected union
councils who intended to deliver at home during the study period and were within the age limit of 15‐49
years and were willing to participate were initially included in the study.
Once fully informed about the goal, procedures for follow‐up, and risks and potential benefits of
participation in the study, the women were requested to provide their consent to participate in the
study and were than registered. A registration form was used for registering each of the eligible
pregnant women in both the intervention and comparison areas (see Annex).
Community education was carried out for each group involved in some way with the study. A
description of the education provided for each group follows.
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1. Pregnant women in the study
In both the intervention and comparison areas, each identified pregnant woman was provided with
information about birth preparedness and danger signs during pregnancy, delivery and the postpartum
period, specifically including information about when to transport a woman in case of complications. In
the intervention areas, each identified pregnant woman was also provided with information about the
safe dose of misoprostol and the method of administration, plus misoprostol’s benefits and side effects.
In the comparison areas, information on misoprostol tablets was not provided.
The counseling sessions with the pregnant women, both in intervention and comparison areas, were
carried out using pictorial booklets and were completed in 2 sessions. The first session was conducted
one month before the expected delivery date and the second 15 days before delivery. The same
information was repeated during both visits. During the second visit, clean delivery kits that included
misoprostol tablets were provided to the women in the intervention areas and clean delivery kits that
did not include misoprostol tablets were provided to the women in the comparison areas.
The clean delivery kits for the women in the intervention areas contained three tablets of 200
micrograms of misoprostol each, along with a pictorial leaflet (Figure 1.2). These pictorial leaflets had
specific information on the correct timing and use of misoprostol. The reason for giving CDKs with
misoprostol to the women in the intervention areas was to ensure the availability of misoprostol at the
time of delivery in case the birth attendant was unable to arrive in time for the birth.
Wrappers of the used misoprostol tablets and the tablets not consumed by the women were collected
by the birth attendants and returned to the social scientist overseeing that area for the study. In total,
6,000 tablets of 200 mcg of misoprostol, under the brand name Misotac, were donated by Venture
Strategies Innovations (VSI) for this study, having been procured from Sigma Pharmaceutical Industries,
Egypt.
2. Female relatives of the pregnant women in the study
The female relatives of the pregnant women in the study, in the intervention and comparison areas,
were provided a briefing on birth preparedness and safe delivery, with an emphasis on the fact that all
deliveries can develop complications. Relatives were informed about the referral system and the
importance and need for making arrangements for shifting the woman to the health facility in a timely
manner in case the woman developed complications. Female relatives in the intervention areas were
also given information on misoprostol.
3. Birth attendants who were expected to handle the deliveries of the women in the study
All of the identified birth attendants (566) were given a one‐day interactive training. These were
conducted by the district supervisor in Khanewal and in Dadu, with the assistance of social scientists
within the selected union councils. All of the birth attendants were trained using a pictorial booklet.
Birth attendants who were unable to come on their particular training day were trained subsequently.
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Figure 1.2: Pictorial booklet/Pictorial instructional leaflet enclosed with CDKs
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In the intervention areas, birth attendants were given information on danger signs during pregnancy,
delivery and the postpartum period, safe delivery, birth preparedness, and when to transfer a women in
case of complications. They were also informed about the availability of misoprostol for the prevention
of PPH, its dose, method of administration, benefits and side effects. In the comparison areas, they were
provided with the same information except they were not given any information on misoprostol.
Clean delivery kits were provided to the birth attendant identified by each woman as the person she
would like to conduct her delivery. Though the majority of birth attendants were TBAs, there were other
categories of attendants as well (see Table 2.5).
4. Lady health visitors
A one‐day training was given to LHVs in the study areas in both districts. The district supervisors
conducted these trainings using a specially prepared training manual. The training emphasized the LHV’s
role in providing back‐up support in case of complications and in making timely referrals to the health
facilities.
5. Male family members of the pregnant women in the study, and community elders and influentials
Logistics supervisors were involved in counseling male family members of the recruited women in both
the intervention and comparison areas. Sessions were carried out in groups, giving the men the
information on timely referral in case of complications at the time of delivery and after the delivery.
Included in these sessions were community elders and influentials who needed to be informed about
the study. Male family members were given the same information as the women and female family
members according to whether or not they were in intervention or comparison areas, including
information on misoprostol (only if they were in an intervention area).
6. Orientation meeting with referral health facility doctors
Meetings were organized with obstetricians of the referral health facilities in both districts. These
physicians were given a detailed briefing on the project and were provided with the referral forms they
were asked to fill out if a case was referred to them from the study areas (both comparison and
intervention).

Data Collection
The second phase of the study involved the data collection. The section on study parameters describes
some aspects of data collection (e.g., quality control, safety measures, etc.). In this section, the
questionnaires used for data collection are described, followed by a description of the data
management and analysis.
Data collection was carried out from November 2009 to June 2010 using a number of data collection
tools, which are described below. Table 1.1 shows the number of data collection tools completed for
each group of study participants.
Questionnaires
Five sets of questionnaires were developed; these had been pretested and amended accordingly. Four
types of questionnaires were used in both the intervention and comparison areas, while the fifth
questionnaire was used only in the intervention areas. (See Table 1.1.)
12
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Questionnaires used in both the intervention and comparison areas:
1. Questionnaire for interviewing pregnant women
This was used to obtain sociodemographic and pregnancy‐related data. This questionnaire was
administered when study teams visited the registered women who agreed to participate in the
study one month before their expected delivery date.
2. Questionnaire for interviewing women during the postpartum period
This was administered within 72 hours of delivery to study participants; information was
obtained on the delivery process.
3. Questionnaire for interviewing women with complications who had been referred to the health
facility.
This was used for interviewing only those women who had been referred to health facilities for
the management of complications.
4. Questionnaire for interviewing birth attendants
All birth attendants who had been involved in the delivery were interviewed after the delivery.
Questionnaire used in the intervention areas only:
5. Questionnaire for interviewing female relatives present at the time of delivery
This questionnaire was administered only in the intervention areas to female relatives of the
women who had recently delivered.
Referral Form
A referral form was also used to obtain detailed information about the cases with complications that
were referred to a health facility. The form was completed by the doctor in‐charge at the facilities where
the referred case was treated in both the intervention and comparison areas. (See Annex.)
Serious Adverse Event Form
A serious adverse event form, developed by the Population Council (New York), was used to obtain
information in case of any serious complication, regardless of cause, occurring in either the intervention
or the comparison areas. When required, this form was completed by one of the project’s district
supervisors, who were medical doctors. (See Annex.)
Verbal Autopsy
Detailed information was obtained, through a verbal autopsy conducted by the district supervisor (a
medical doctor) and reviewed by a nosologist, for any maternal death that occurred.
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Table 1.1: Number of study participants who completed specified questionnaires/forms, according to areas
Variable
Pregnant women 15‐49 who met study criteria: completed
in‐take questionnaire (including women with past C‐
sections)
Study women interviewed after birth: completed
postpartum questionnaire (including women with
present C‐sections)
Study women referred for complications: completed
referral questionnaire (including women with present C‐
sections)
Birth attendants involved in deliveries: completed post‐
delivery birth attendant questionnaire
Family members present at time of delivery: completed
post‐delivery family questionnaire (intervention areas
only)
Doctors in‐charge at referral medical facilities where
complications were referred: completed referral form
Verbal autopsy

Intervention
areas

Comparison
areas

Total

872

826

1,698

782

727

1,509

87

94

181

303

263

566

872

0

872

87

94

181

3

5

8

1

Of these women, 55 in the intervention areas were removed from the final analysis because they were identified for Cesarean
sections. There were 77 in the comparison areas who were identified for Caesarean sections.

Data Management/Data Analysis
The team leaders sent the completed quantitative questionnaires to the Population Council office in
Islamabad. Prior to commencing data entry, the questionnaires were edited. The data were entered,
and range skip and filter checks were applied to minimize errors and omissions. The data were then
coded and entered using CSPro (version 3.2) and SPSS (version 14). Results were summarized using
frequency distributions and cross tabulations. All study data and forms were stored in locked cabinets at
the Population Council office in Islamabad.

Limitations of the Study
The study design was quasi‐experimental and the area selection was not randomized. In the absence of
sufficient research on assessing the compliance of misoprostol ingestion within home settings, it is
difficult to make comparisons across regions. Although not an identified objective, we did ask for
women’s experiences of postpartum bleeding within the intervention and comparison areas; this was
based on perceptions rather than actual measurements.
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CHAPTER 2. CHARACTERISTICS OF
PARTICIPANTS
Characteristics of Women
In the first section of this chapter, characteristics of the study women from the intervention and
comparison areas are compared. One general characteristic was that the commonly spoken languages in
both intervention and comparison areas were Punjabi, Sindhi and Saraiki.

Age
Out of a sample of 872 women in the intervention areas and 826 women in the comparison areas who
had agreed to participate in the study, the largest age group, about a third of the women in both areas,
was 25‐29 years of age (Figure 2.1). The smallest age groups were 40‐44 and 45‐49 years, with 3 percent
or less. About 7 percent in both the intervention and comparison areas were ages 15‐19 years. The
mean age was 28 years in both the intervention and comparison areas. [Note: SD=5.7 intervention
areas; SD=6.0 comparison areas.]
Figure 2.1: Percentage distribution of women, by areas, according to age groups
1
1
16

1
3
12

21

20

45 ‐ 49
40 ‐ 44
35 ‐ 39

35

34

30 ‐ 34
25 ‐ 29
20 ‐ 24

15

19

23

7

7

Intervention areas

Comparison areas

15 ‐ 19
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Education
As shown in Figure 2.2, a majority of the women in the intervention and comparison areas were not
educated. A negligible proportion of women reported receiving education beyond the secondary level.
Among the women who attended school, more were found in the primary education group. Mean
education in the intervention areas was 1.7 years and 1.3 years in the comparison areas. [Note: SD=3.1
intervention areas; SD=2.8 comparison areas.]
Figure 2.2: Percentage distribution of women, by areas, according to education

1
9
16

1
7
14
Above secondary (>10)
Up to secondary (Class 6‐
10)

73

78

Up to primary
(Class 1‐5)
No education

Intervention areas

Comparison areas

Women’s Husbands
Education
As shown in Figure 2.3, more than two‐fifths of the husbands, in both intervention and comparison
areas, were uneducated: 41 percent ‐ intervention areas; 47 percent ‐ comparison areas. However,
slightly more than a quarter had attained an education at or beyond class 6. Those who were educated
above secondary school made up only a small percentage. The mean number of years of schooling in the
intervention areas was 4.8 and in the comparison areas it was 4.1. [Note: SD=4.7 intervention areas;
SD=4.4 comparison areas.]

16

Characteristics of Participants

Figure 2.3: Percentage distribution of husbands, by areas, according to education
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Occupation
A majority of the husbands in both areas were self‐employed (Table 2.1). The second most common
profession was government service. The percent engaged in private service was close to 4 percent in
both areas.
Table 2.1: Percentage distribution of husbands, by areas, according to occupation
Occupation
Self employed
Government service
Private service
Unemployed
Other
Don’t know

Intervention areas
81.5
9.1
4.7
4.1
0.6
0.1

Comparison areas
88.8
4.4
4.2
2.2
0.2
0.1

Live Births (Parity)
The proportions of women having 0 children and 1‐2 children were similar in both areas, about 20 and
31 percent respectively. The proportion of women having 3‐5 children was 29 percent in the
intervention areas and 34 percent in the comparison areas (Table 2.2).
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Table 2.2: Percentage distribution of women, by areas, according to live births, stillbirths, abortions and
antenatal care visits
Variable
Number of live births
0
1‐2
3‐5
5+
Mean number of live births
Number of stillbirths
0
1
2
3
4 or more
Number of abortions (spontaneous and induced))
0
1
2
3
4
Number of antenatal visits
At least 1 antenatal visit
No antenatal visit
(N)

Intervention areas

Comparison areas

20.1
30.8
29.1
20.0
3.0

20.6
31.4
33.7
14.4
2.8

91.6
6.5
0.9
0.7
0.2

87.9
8.5
1.8
0.9
1.0

75.1
16.1
6.7
1.3
0.9

74.0
17.4
5.6
2.1
1.0

56.3
43.7
(872)

58.8
41.2
(826)

Stillbirths
About 90 percent of the women in both areas never had a stillbirth (Table 2.2). Among those who had
stillbirths, the majority in both intervention and comparison areas had only one stillbirth.

Abortions
About three‐quarters of the women in both areas never had an abortion (Table 2.2). The smallest
proportion in both areas belonged to the group with 4 or more abortions (≤1 percent). Out of the total
abortions in the intervention areas, 95 percent were spontaneous abortions and 5 percent were induced
abortions; in the comparison areas, 96 percent of the total abortions were spontaneous and 4 percent
were induced.

Antenatal Care
Antenatal care is defined as an examination of a woman by a skilled health care provider during
pregnancy. According to WHO, four antenatal visits are recommended during pregnancy. Close to 60
percent of the women in both the intervention and comparison areas had made at least one antenatal
visit, (p=0.29) showing no statistically significant difference between the two areas (Table 2.2).
Provider
As shown in Table 2.3, a majority of the women who had antenatal checkups went to an MBBS doctor:
80 percent ‐ intervention areas; 86 percent ‐ comparison areas. A very negligible percentage mentioned
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receiving antenatal care from a dai.
Table 2.3: Percentage distribution of women, by areas, according to who provided their antenatal care
Provider
MBBS doctor
Nurse
LHV
Dai/TBA
Community midwife
Other
(N)

Intervention areas
79.6
10.4
4.9
3.1
1.0
0.8
(490)

Comparison areas
85.8
7.8
1.0
3.5
1.2
0.4
(486)

Procedures
As Table 2.4 shows, among women who had an antenatal checkup, more than 70 percent in both
intervention and comparison areas had an ultrasound examination. Essential components of an
antenatal checkup ‐‐ blood test and urine test ‐‐ were each done in only 5 percent of the cases in the
intervention areas, while in comparison areas a blood test was done in 10 percent of cases and a urine
test in 5 percent.
Table 2.4: Percentage distribution of women, by areas, according to checkup components
Component
Blood deficiency checked
Blood pressure checked
Ultrasound performed
Fetal position checked
Weight measured
Blood test performed
Urine test performed
Fetal heart rate checked
Other
(N)

Intervention areas
34.5
34.9
70.4
32.2
4.1
4.9
5.1
11.2
1.4
(490)

Comparison areas
28.6
49.2
73.9
33.7
15.2
9.5
5.1
28.2
0.4
(486)

Multiple response variable.

Characteristics of Birth Attendants
Type
Many of the women in the study used the services of the same birth attendants. There were a total of
566 attendants who helped study women deliver their babies both at home and at health facilities.
About 80 percent of the birth attendants in both the intervention and comparison areas were traditional
birth attendants/dais (Table 2.5). MBBS doctors were the second major group, but only 6 percent in the
intervention areas and about 10 percent in the comparison areas.
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Table 2.5: Percentage distribution of birth attendants, by areas, according to type
Type of birth attendant
Untrained birth attendant/dai
MBBS doctor
LHV
CMW
Nurse
Homeopathic doctor
FWW
Midwife
Relative
(N)

Intervention areas
79.5
5.9
4.9
2.9
0.7
0.3
1.0
0.3
4.6
(303)

Comparison areas
81.4
9.7
4.5
1.9
1.5
0.4
0.4
0.0
0.4
(263)

Age
More than a quarter of the birth attendants in the intervention areas were in the age group 45‐54 years
and almost a similar number were 55‐64 years of age. In the comparison areas, close to one‐third
belonged to each of the age groups 45‐54 years and 55‐64 years. Only small percentages were in the
youngest age groups or the oldest age groups in both the intervention and comparison areas (Table 2.6).
Table 2.6: Percentage distribution of birth attendants, by areas, according to sociodemographic variables
Variable
Age
15‐24
25‐34
35‐44
45‐54
55‐64
65‐74
75‐85
Education
No education
Up to primary (class 1‐5)
Up to secondary (class 6‐10)
Up to intermediate (up to class 12)
Up to graduation (up to class 14)
Up to masters/medical graduates (class 16)
Marital status
Married
Widow
Separated
Single
(N)

Intervention areas

Comparison areas

1.7
7.6
19.5
28.1
26.1
14.2
3.0

0.8
5.3
13.7
28.9
31.2
19.0
1.1

71.0
7.9
9.2
2.3
1.3
8.3

72.2
5.7
7.6
3.0
1.5
9.9

64.7
30.0
1.0
4.3
(303)

57.5
39.9
0.0
2.7
(263)

Note: Total number of birth attendants in both areas was 576 but 10 were in accessible and could not be interviewed . They
have been excluded from the analysis.

Education
Just over 70 percent of the birth attendants in both areas were illiterate. However, about 8 percent in
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the intervention areas and 10 percent in the comparison areas had post‐graduate degrees or were
medical graduates (Table 2.6).

Marital Status
A major proportion of birth attendants were currently married: 65 percent in the intervention areas and
58 percent in the comparison areas. Widows were the second most common group in both areas. Only a
small percent of the birth attendants were single (Table 2.6).

Work Experience
Most of the birth attendants in both areas had a great deal of work experience, as shown in Figure 2.4.
Only a very small percentage had less than a year of work experience.
Figure 2.4: Percentage distribution of birth attendants, by areas, according to years of work experience

20
10

23
14

21 to 25 years

20
19

16 to 20 years
11 to 15 years

17
16
18

More than 25 years

15

6 to 10 years
Less than 5 years
No experience

13
3

13
1

Intervention areas

Comparison areas

Chapter Summary
The data presented in this chapter show that respondents in both groups had similar characteristics.
This chapter also provides a profile of birth attendants in rural communities and shows that traditional
birth attendants are still the most popular source for maternal and child health care in rural areas. The
birth attendants in this study were mostly middle‐aged women, who were currently married or, to a
lesser degree, widowed. One implication is that for widowed village women a career as a birth
attendant or dai is a respectable option for earning a livelihood.
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CHAPTER 3. KNOWLEDGE: POSTPARTUM
HEMORRHAGE AND MISOPROSTOL
This chapter presents information about the knowledge of postpartum hemorrhage and misoprostol
retained by the pregnant women from their initial briefing session carried out during the registration
process. The knowledge of the birth attendants who conducted the births of study women was also
obtained in a questionnaire that was conducted within 72 hours of the births.

Women’s Knowledge
At the initial contact with the pregnant women, they had been given a short briefing about the study to
help them decide if they were interested in participating. This briefing included information on
pregnancy, pregnancy care, birth preparedness, and danger signs in pregnancy. For the pregnant
women in the intervention areas, information was also provided on misoprostol. When the study teams
visited the pregnant women one month before their expected delivery dates, and before giving them a
more in‐depth counseling session on all of the topics presented during the briefing, they were
interviewed and their knowledge and perceptions regarding postpartum hemorrhage (and misoprostol
for those in the intervention areas) were assessed. This was done to determine how much of the initial
briefing information had been retained because the ability of the pregnant women to internalize the
messages about these important pregnancy‐related topics was considered an important indicator for
compliance. The thinking was that if the women could appreciate why it was important for them to take
misoprostol, they would be better prepared to do so. Furthermore, accurate knowledge might well
translate into taking the tablets at the correct time and dosage.

Postpartum Hemorrhage
Danger
Postpartum hemorrhage is defined as excessive blood loss of 500 ml or more from the genital tract in
the first 24 hours following delivery. About 98 percent of women in the intervention areas and 72
percent in the comparison areas perceived that postpartum hemorrhage could be potentially dangerous
(Table 3.1). Two percent of the respondents in the intervention areas and 27 percent in the comparison
areas did not consider PPH to be dangerous.
Among the women who did not consider PPH to be dangerous, nearly a quarter in both areas believed it
to be a normal phenomenon. Of those who thought PPH was not dangerous, 14 percent in the
intervention areas and more than 20 percent in the comparison areas thought home remedies were
effective or that the dai could easily manage the hemorrhage (Table 3.1).
Causes
When asked about the causes of postpartum hemorrhage, more than one‐third of the women in the
intervention areas said that it was caused by retained products of the placenta and another third said
delayed delivery of the placenta (spontaneous response). This increased to about 56 percent each upon
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prompting. In the comparison areas, about 10 percent of the respondents considered retained products
of placenta (spontaneous response) as a cause of postpartum hemorrhage and fewer thought delayed
delivery was a cause (Table 3.2). Upon promoting cervical tears and uterine rupture were considered as
an important cause by more than three‐quarters of the respondents in the intervention areas and 60
percent in the comparison areas.
Table 3.1: Percentage distribution of women, by areas, according to perceptions and knowledge about
postpartum hemorrhage
Variable
Perceptions about PPH
Dangerous
Not dangerous
Don’t know
(N)
Reasons why women thought PPH was not dangerous
Normal phenomena
Home remedies are effective
Dai can easily manage
Don’t know
Other
(N)
Signs and symptoms indicating need to refer for PPH*
Skin cold, wet and pale (fainting)
Unconsciousness
Heavy bleeding continues even after home management
Uterus comes out with placenta
Don’t know
Others
(N)
Appropriate timing for referral
Within 1‐2 hours of heavy bleeding
Within 2‐3 hours of heavy bleeding
Within 3‐4 hours of heavy bleeding
Other
Don’t know
(N)
*Multiple response variable.
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Intervention areas

Comparison areas

97.6
2.4
0.0
(872)

72.3
27.1
0.6
(826)

23.8
14.3
14.3
47.6
0.0
(21)

24.6
21.9
25.9
27.2
0.4
(224)

41.0
20.8
20.2
2.8
26.3
1.2
(851)

44.6
33.0
20.8
7.4
21.4
0.7
(597)

93.5
1.1
0.6
1.2
3.6
(851)

88.9
5.0
0.8
0.5
4.9
(597)

Knowledge: Postpartum Hemorrhage and Misoprostol

Table 3.2: Percentage distribution of women, by areas, according to knowledge about causes of PPH*
Intervention areas
Cause
Uterine atony
Retained products of placenta
Delayed delivery of placenta
Vaginal tears
Cervical tears
Uterine rupture
(N)

Knowledge
Spontaneous
Prompted

3.7
36.4
33.1
4.6
6.4
6.2

68.1
57.6
56.3
75.6
78.3
81.2

Comparison areas
None

28.2
6.0
10.6
19.7
15.3
12.6

Knowledge
Spontaneous
Prompted

0.91
10.2
6.8
7.9
4.3
5.0

(872)

42.5
66.3
56.8
62.4
60.6
66.1

None

56.6
23.5
36.4
29.6
35.1
29.0

(826)

*Multiple response variable.

Referral
Signs that referral is needed. Women who considered PPH to be dangerous were asked about the signs
and symptoms to look for that could indicate a women needs to be referred to a higher‐level facility. As
seen in Table 3.1, more than 40 percent of the respondents in both areas considered that a woman with
postpartum hemorrhage should be referred when her skin becomes cold, wet and pale. The second
most common reason for referral was if she becomes unconscious. A quarter of the respondents in the
intervention area and one‐fifth in the comparison areas did not know the signs and symptoms that
warrant the transfer of a woman to a referral facility.
Timing of referral. Respondents in both areas who considered PPH to be dangerous were asked when
they thought a woman suffering from PPH should be referred to a health facility (Table 3.1). Most
women correctly identified the timing as within 1‐2 hour of heavy bleeding; 94 percent ‐ intervention
areas; 89 percent ‐ comparison areas.

Misoprostol

Table 3.3: Percent distribution of women in intervention
areas, according to knowledge about misoprostol

Women in the intervention areas had been
provided with information on misoprostol’s
advantages and use at the initial briefing Variable
Knowledge that tablet taken orally can
session, in addition to the same pregnancy
prevent PPH (N=872)
related information given to the women in Knowledge of name of tablet (N=827)
the comparison areas. Most of the women
Could recall name
(95 percent) in the intervention areas
Could not recall name
mentioned that tablets taken orally could Knowledge of administration (N=798)
prevent PPH. As shown in Table 3.3, about
Correct knowledge
52 percent of these women were able to
Incorrect knowledge
recall the name of the drug misoprostol
naming it as “Miso”, while 48 percent could not do so.

Intervention
areas
94.8
51.9
48.1
91.9
8.1

Among those who knew about misoprostol, 92 percent of the women knew, correctly, that misoprostol
should be ingested immediately after delivery of the baby and before delivery of the placenta; only 8
percent did not remember the proper time for administering misoprostol (Table 3.3).
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Birth Attendants’ Knowledge
All of the birth attendants who had delivered women participating in the study, whether at home or at
the health facility, were interviewed within 72 hours after the delivery, and their knowledge of PPH and
misoprostol was assessed.

Postpartum Hemorrhage
A very high proportion of birth attendants (around 95 percent) in the intervention and comparison areas
were able to correctly identify postpartum hemorrhage (Table 3.4).
Table 3.4: Percentage distribution of birth attendants, by areas, according to knowledge about PPH and
misoprostol
Variable
Knowledge of PPH
Know
Don’t know
(N)
Knowledge of misoprostol name
Could recall name of tablet
Could not recall name of tablet
Knowledge of timing for administration of misoprostol
Correct timing
Incorrect timing
Knowledge of side effects of misoprostol*
Shivering/chills
Fever
Nausea
Vomiting
Abdominal pain
Don’t know
Other
*Multiple response variable.

Intervention areas

Comparison areas

95.7
4.0
(303)

95.0
5.0
(263)

60.0
40.0

na
na

98.0
2.0

na
na

78.0
66.7
25.1
37.6
22.0
8.2
1.2

na
na
na
na
na
na
na

na=not applicable

Misoprostol
When asked about misoprostol in the intervention areas, most of the birth attendants (60 percent)
could recall the name of the tablet. Close to all of the birth attendants (98 percent) knew the correct
time for administering misoprostol. (See Table 3.4.)
About 78 percent of the birth attendants knew shivering is one of the side effects of misoprostol, and 67
percent knew about fever, while smaller percentages knew about other side effects (Table 3.4).

Chapter Summary
After their initial briefing session, a very high proportion of the pregnant women had a clear concept of
what constitutes postpartum hemorrhage, why it is dangerous and what causes it. While 95 percent
women in the intervention areas knew that an oral drug could help in preventing PPH, around half could
also name it. A high proportion of the birth attendants also retained information about PPH and
misoprostol that they had been given during their interactive training.
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CHAPTER 4. MISOPROSTOL USE: SAFETY,
ACCEPTABILITY, REFERRAL
The primary purpose of this research was to evaluate a process that motivated women giving birth at
home to take misoprostol, and to take it correctly, and to obtain the cooperation of birth attendants.
Apart from compliance, the satisfaction of the women who took misoprostol was also elicited based on
their willingness to recommend the drug to others and to purchase it in future. These women were also
asked about any side effects they experienced as a result of taking misoprostol. Women in both
intervention and comparison areas were asked about their experience of postpartum bleeding.

Safety
Use
Out of the 890 women identified in the intervention areas as pregnant, 872 agreed to participate in the
study, while 18 refused. Out of the 872 who agreed to participate, 770 delivered at home and were
eligible for misoprostol. Among the remaining, 55 were deemed ineligible due to past history or present
indication for having a C‐section. Additionally, 47 women were excluded due to referral to a facility
before delivery for obstetric complications identified during labor.
In the comparison areas, 826 agreed to participate in the study, and 720 women who had home
deliveries were included. The other 106 women either had a history of C‐sections (77 women) and were
ineligible or were referred to a facility for other obstetric complications (29 women) and excluded from
the analysis.
As seen in Table 4.1, 770 eligible women who delivered at home. Out of these 678 (88 percent) ingested
misoprostol tablets provided to them in the clean delivery kits, while 92 women (12 percent) did not.
Bivariate analysis revealed no statistically significant difference for number of living children or
husband’s education on the intake of misoprostol tablets.
Table 4.1: Distribution of women according to misoprostol use and other variables
Variable
Place of delivery
Home (N=770)
Number of living children (P=0.08)
0‐1 (N=330)
2 or more (N=484)
Education of husbands (P=0.9)
Never attended school (N=332)
Ever attended school (N=479)
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Did not use misoprostol
Number
Percent

Used misoprostol
Number
Percent

92

11.9

678

88.0

33
68

10.0
14.0

297
416

90.0
86.0

41
60

12.3
12.5

291
419

87.7
87.5
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Timing and Dosage
The recommended time and dosage of misoprostol administration is three tablets to be ingested after
the birth of the baby but prior to the delivery of the placenta. Women who delivered at home 647(84
percent) took the tablets correctly (correct time and correct dose) (Table 4.2). No woman took the
tablets before the birth of the baby. There were three twin deliveries in the intervention areas; all of the
women delivering twins took the tablets correctly, after the birth of the second twin.
Table 4.2: Distribution of women who used misoprostol, according to variables of use
Variable
Dose and timing
Misoprostol taken correctly (correct time and correct dose: three
tablets, after birth, before delivering placenta)
Misoprostol taken incorrectly (incorrect time or incorrect dose)
Side effects (N=647)
No side effects
Side effects (total)*
Shivering/chills
Fever
Vomiting
Nausea
Abdominal pain

Number

Percent

647
31

84.0
4.0

387
260
178
68
23
43
42

59.8
40.1
69.3
26.5
8.9
16.7
16.3

*Multiple response variable.

Side Effects
The 647 women who took misoprostol tablets correctly (correct dose and correct time) were asked
about the side effects and 40 percent reported that they had experienced side effects (Table 4.2). The
majority reported suffering shivering/chills (69 percent), followed by fever (27 percent) and nausea (17
percent). However, in all these cases, the symptoms were transient and did not require referral for
specialized care.

Acceptability
Women
As seen in Table 4.3, 91 percent of the women who delivered at home said that they would use
misoprostol in the future (94 percent in Dadu; 89 percent in Khanewal). When the women who said they
would use misoprostol in the future were asked if they would also be willing to purchase the tablets, 93
percent expressed their willingness to do so (99 percent in Khanewal; 87 percent in Dadu). Overall,
almost 100 percent of the women who used misoprostol during their home deliveries and said that they
would be willing to use misoprostol in the future also said that they would recommend misoprostol to
others (only 2 were not willing to recommend misoprostol to others).
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Table 4.3: Distribution of women who used misoprostol and delivered at home, according to variables indicating
acceptability of misoprostol
Khanewal
Willing

Variable
Take in future
Purchase in future
Recommend to others

N
309
305
309

Dadu

Not willing

%
88.5
98.7
100.0

N
40
4
0

%
11.5
1.3
0.0

Willing

N
305
268
305

Total

Not willing

%
93.6
87.3
99.3

N
21
39
2

%
6.4
12.8
0.7

Willing

N
614
571
614

%
91.0
93.0
99.7

Not willing

N
61
43
2

%
9.0
7.0
0.3

A total of 92 eligible women in the intervention areas who had agreed to use misoprostol did not take
the tablets after delivery (Table 4.4). The main reason the women gave for not taking misoprostol was
that they forgot; in 22 cases, respondents forgot to take the tablets because of what was described as
an emergency situation. Family opposition was seen to be negligible, with only 13 cases reporting
hindrance from relatives. Out of these 13 cases, there was only one woman who reported that her
husband opposed the use of misoprostol.
Table 4.4: Distribution of women, according to the main reason for not taking misoprostol
Reason
Self reservation
Family members opposed
Forgot
TBA / dai opposed
Other
Total

Number
11
13
49
11
08
92

Percent
11.9
14.3
53.2
11.9
8.7
100.0

Respondents who were willing to purchase misoprostol tablets in the future were asked about the
amount they would be willing to pay. Just over half of the women in both districts said that they would
be willing to pay up to Rs. 25 for the three tablets (Table 4.5).
Table 4.5: Distribution of women, according to the amount (in Pakistan rupees) they would be willing to pay for
misoprostol, by district
Amount
1‐25
26‐50
51‐100
>100
Total

Khanewal
Number
Percent
137
45
50
17
249

55.0
18.1
20.1
6.8
100.0

Dadu
Number
Percent
97
65
21
8
191

50.8
34.0
11.0
4.2
100.0

Total
Number
Percent
234
110
71
25
440

53.2
25.0
16.1
5.7
100.0

Birth Attendants
Another indicator of the acceptance of misoprostol is that 98 percent of the birth attendants in the
intervention areas who had administered misoprostol tablets and knew the name of the tablets (60
percent of all birth attendants) said that they would recommend the tablets to other clients.
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Referrals
Referrals for Management of PPH
As Table 4.6 shows, 3 women in the intervention areas (0.38 percent) suffered from postpartum
hemorrhage that required referral to a higher‐level facility. Out of these, 2 had ingested misoprostol and
1 had not. The woman who had not ingested misoprostol died on reaching the facility, while the other 2
were discharged after receiving routine management. All 3 referred women from the intervention areas
were above the age of 30, and 2 were grand multipara, while one had 3 children. In the comparison
areas, 5 women (0.64 percent) were referred for severe PPH. Out of these, 2 died before reaching the
appropriate facility. The number of referrals due to postpartum hemorrhage was lower than anticipated
while calculating the sample size.
Table 4.6: Distribution of PPH referrals and deaths (as percents of all referrals and all deaths), by areas
Intervention areas
Number
(N=770)
Percent

Variable

Comparison areas
Number
(N=720)
Percent

Referrals for PPH

3

0.38

5

0.64

Deaths due to PPH

1

0.12

2

0.27

The smaller percents in the intervention areas, although based on small numbers, are given credence by
women’s perceptions of heavy bleeding by area and use of misoprostol.
Perception of Bleeding in Postpartum Period
Among the 770 women in the intervention areas and 720 women in the comparison areas who
delivered at home, 5.1 percent in the intervention areas and 11.3 percent in the comparison areas
perceived heavy bleeding (Table 4.7). It was seen that women in the comparison areas were twice as
likely to perceive suffering from heavy bleeding as compared to the intervention areas, with a
statistically significant difference.
Table 4.7: Distribution of women who had home deliveries, by areas, according to perception of excessive
postpartum vaginal bleeding, by areas

Area

Not perceived

Perception of heavy bleeding
Percent
Perceived
Percent

Odds ratio

Comparison

638

88.6

82

11.3

1

Intervention

730

94.8

40

5.1

0.42

P value=0.00

Perception of Bleeding in Postpartum Period and Misoprostol Intake
While examining perception of postpartum bleeding with the correct or incorrect intake and no intake
of misoprostol we found that respondents who correctly took misoprostol were less likely to have
perceived heavy bleeding in the postpartum period (Table 4.8).
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Table 4.8: Distribution of women who had home deliveries, by correct intake, incorrect intake and no intake of
misoprostol tablets, according to perception of excessive postpartum vaginal bleeding
Perception of heavy bleeding
Area

Not
perceived

Percent

Perceived

Percent

Odds ratio

P value

29

93.5

2

6.5

0.53

0.4

615

95.6

32

4.9

0.40

0.00

86

85.0

6

15.0

0.76

0.5

Intervention
(incorrectly taken)
Intervention
(correctly taken)
Not taken
Comparison area is the reference

Referrals Due to Other Obstetric Complications and MMR
In the intervention areas, 47 women were referred to a health facility by the available birth attendant
due to obstetric complications before delivery; while in the comparison areas 29 women were referred.
Table 4.9 shows the distribution of all referrals by cause. Besides mortalities due to PPH, 2 other
obstetric deaths occurred in the intervention areas and 3 additional obstetric deaths took place in the
comparison areas. Total deaths in the intervention areas were 3. Apart from PPH, the other causes of
mortality were antepartum hemorrhage and eclampsia. In comparison areas, there were 5 deaths. Apart
from PPH the other causes of mortality included complications of cancer of the larynx, uterine rupture
and cardiac disease. Maternal mortality ratio (MMR) in the intervention area was 344/100,000 live
births and 605/100,000 live births in the comparison area.
Table 4.9: Distribution of all referrals in intervention and comparison areas, by cause
Intervention areas

Comparison areas

Number of
referrals

Percent

3

6.4

33

70.2

Malpresentation (breech)

4

8.5

Premature rupture of
membrane

2

4.3

Postpartum hemorrhage

3

6.3

Self‐referral

2

4.3

47

100.0

Cause
Antepartum hemorrhage
Prolonged labor

Total

Number of
referrals

Percent

3

10.3

18

62.1

1

3.4

1

3.5

Postpartum hemorrhage

5

17.2

Self‐referral

1

3.5

29

100.0

Cause
Antepartum hemorrhage
Prolonged labor
Malpresentation (breech)
Premature rupture of
membrane

Total
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Chapter Summary
Results from this chapter demonstrate that through proper counseling and information exchange it is
possible to introduce a new intervention in rural communities. Of the eligible women delivering at
home, 88 percent took the tablets and out of these 84 percent were able to take the correct dose at the
right time, despite the women’s high level of illiteracy. The side effects reported by the women were of
a transient nature and did not require hospital management.
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CHAPTER 5. DISCUSSION AND
RECOMMENDATIONS
Discussion
In Pakistan, around 60 percent of the population resides in rural areas, often not near health facilities,
which tend to be concentrated in urban areas. With 61 percent of deliveries still being carried out by
unskilled birth attendants at home, Pakistan is one of the few countries in the region that continues to
have a high maternal mortality ratio. Due to the paucity of emergency obstetric care facilities,
encouraging institutional deliveries is not a viable option for improving maternal outcomes at this time.
For this reason, the government of Pakistan introduced the national MNCH program in 2006. A goal of
this program is to employ 12,000 trained community midwives to improve access to skilled birth
attendants in rural communities. At present, the deployment of these workers has been limited, as few
have been able to meet their placement requirements. Those who have returned to their respective
communities require some time before they are fully established and recognized as a viable and
worthwhile alternative to the existing traditional birth attendants.
To make pregnancy safer, an interim strategy has to be introduced until such time that community
midwives are in a position to completely replace traditional birth attendants. One approach is to train
the existing TBAs to adopt skills that can make their practice safer. Such an approach has been tried in
many parts of the world but with mixed results. In Pakistan the Population Council, through the Safe
Motherhood Applied Research and Training Project (Miller and Rashida, 2006), was able to demonstrate
a 22 percent fall in perinatal mortality through community awareness and training of traditional birth
attendants (in DG Khan district, Punjab province). A study, using a cluster randomized controlled trial in
Sindh province, showed a significant reduction in perinatal mortality in intervention clusters where TBAs
were trained (Jokhio, Winter and Cheng, 2005).
The Pakistan Demographic and Health Survey 2006‐07 shows that the leading cause of maternal
mortality in Pakistan is postpartum hemorrhage. Globally, efforts are underway to improve the
prevention of postpartum hemorrhage through advocating the active management of the third stage of
labor (AMTSL). Empirical evidence shows that the administration of uterotonic drugs in the third stage
of labor can markedly reduce the incidence of PPH. Among the safest options available are the
injectable drugs oxytocin and methergin; however, both require skilled attendants for administration
and, being heat labile, special storage conditions. In resource‐constrained settings, misoprostol provides
a good alternative because it is inexpensive, heat stable, taken orally, has a long shelf life and can be
administered within thpe home setting. While WHO does not recommend misoprostol use over
injectable oxytocin, it recognizes the problems associated with the use of oxytocin in rural communities
and, therefore, encourages more research on the use of misoprostol.
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The Ministry of Health and Family Welfare in India has endorsed the use of misoprostol for deliveries in
rural settings, (Ministry of Health and Family Welfare, 2005). In January 2006, the Nigerian health
agency also approved the use of misoprostol tablets, initially in hospital and clinic settings, for the
prevention and treatment of postpartum hemorrhage (Greensfelder, 2006).
While the efficacy of misoprostol has been well established, the feasibility of its administration in
societies that are very closely governed by traditional values has not been documented extensively. As
in many developing countries, rural communities in Pakistan are steeped in traditions and cultural
norms, including those followed by traditional birth attendants, who have usually learned their skills
from previous generations of TBAs in their families whose practices are at times detrimental to health.
Emerging evidence shows that trained community health workers can be utilized to distribute
misoprostol tablets through a home‐based approach. For instance, in a study from Indonesia,
researchers trained community volunteers to provide women with information about the prevention of
postpartum hemorrhage, give them misoprostol tablets, and provide follow‐up support. This
community‐based approach was noted as being safe and acceptable to the women, contributing to their
willingness and ability to use the drug appropriately (JHPIEGO, 2004).
In another study, from Afghanistan, it was seen that through proper education 70 percent of the eligible
women used misoprostol in the target communities (Sanghvi et al., 2010). Another study, from rural
Tanzania, also shows that after training TBAs, they were able to recognize and manage PPH effectively
(Prata et al., 2005).
This OR study was designed to test, on a large scale, the hypothesis that it is feasible to safely distribute
600 micrograms of misoprostol through birth attendants trained in its use, who would ensure that the
drug was taken correctly by women delivering at home. Our results show that 88 percent of eligible
women ingested the drug (90 percent compliance in Khanewal and 84 percent in Dadu), reinforcing the
assumption that proper counseling and training can alter well‐entrenched behaviors and practices. Our
results also show that side effects, experienced by 41 percent of the women who took the drug, were
transient and did not require any specific management. In fact, this did not prevent 91 percent of the
women who took misoprostol at home from saying that they would take the drug for future deliveries.
Nearly 100 percent of the women who took misoprostol at home and said they would be willing to use it
in future also expressed their willingness to recommend the drug to others.
In this study, as in the study in Indonesia, the safety and acceptability of the drug, and the feasibility of
creating awareness about misoprostol and managing distribution of the tablets, were considered key to
the successful use of misoprostol to prevent PPH. Three important factors contributed to the proportion
of women who accepted and used the tablets. First and foremost was community awareness, which, to
a great extent, was facilitated by local lady health workers (LHWs) targeting community pregnant
women and their family members; second, and also part of community awareness, were discussions
with community elders and influentials; and, third were the counseling sessions that provided accurate
and credible information directly to the women, their family members and husbands, and birth
attendants, and included culturally appropriate IEC materials. Women who were given the misoprostol
tablets were briefed using a pictorial booklet designed especially for this purpose. Another pictorial
instruction sheet was enclosed in the clean delivery kits that contained misoprostol tablets. We found
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that both the use of the booklet and the instruction sheet in counseling the pregnant women and their
chosen birth attendants, including next of kin, greatly contributed to the high rate of women using the
tablets correctly and safely (84 percent of the women used the tablets correctly at home).
After providing information regarding postpartum hemorrhage and misoprostol, we interviewed the
women close to their time of delivery to see what information they had retained. Our research shows a
high level of awareness in women regarding postpartum hemorrhage, with a substantially high
proportion of them holding the view that postpartum hemorrhage is potentially dangerous. Another
heartening finding was that the majority knew the point at which it was necessary to refer a woman in
case of postpartum hemorrhage. Nearly half of the respondents in the intervention area (52 percent)
remembered the name of misoprostol (most referred to it as “miso”).
An indicator related to the correct use of misoprostol is the number of referrals. In our study, we found
that the number of women who were referred for PPH‐related complications was nearly half those in
the comparison areas. Although the numbers are small, 3 women were referred from the intervention
areas, while 5 were referred from the comparison areas. Furthermore, the women in the intervention
areas perceived less bleeding in the postpartum period as compared to the comparison areas. As for
maternal mortality, there was one death from PPH reported in the intervention areas (in this case, the
woman had not taken misoprostol tablets) and two PPH‐related deaths in the comparison areas. These
facts indicate that women in the intervention areas were less likely to be transferred to a higher‐level
facility than women in the comparison areas. In total, there were 4 maternal deaths in the intervention
areas and 5 deaths in the comparison areas.
In the intervention areas of our study, we provided clean delivery kits to both the birth attendants and
the pregnant women to ensure that a clean delivery kit and misoprostol tablets were available at the
time of delivery, in case the birth attendant did not arrive at the delivery in time.
A majority of the 12 percent of the women who did not take misoprostol said that they forgot to take
the tablets on time. This reaffirms the need to remind women to keep the tablets readily available once
labor pains commence.
Another finding from our study that may have programmatic implications is that the majority of the
TBAs were married and in the middle age groups, the next largest group was widows. The national
MNCH program may try to target widows who are self‐supporting and require a respectable way of
making a living.
Results from a study in Egypt recommend the use of misoprostol even in hospital settings if there are
staff shortages, refrigeration issues and/or high caseloads, since misoprostol offers the advantage of a
one‐drug regimen, stability and easy administration, as compared to injectable uterotonics (Prata et al.,
2006).
The results from our study provide a useful addition to the literature on the feasibility of home‐based
administration of misoprostol in the region, furthering the case for inclusion of the drug in the protocol
for active management of the third stage of labor at the community level. Our study also dispels the
notion that TBAs cannot contribute to lowering maternal mortality: by introducing a simple, low‐cost,
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easy‐to‐use technology, TBAs can play a role in reducing one of the largest single causes of maternal
deaths.

Recommendations
•

Train community based providers in the use of misoprostol in resource constrained settings
The results from our study further substantiate the already available empirical evidence that
recommends the use of misoprostol in resource‐constrained settings by community providers. For
this purpose training needs to be imparted to LHW’s and community midwives in the use of
misoprostol including its dosage, side effects and their management.

•

Empower families to make pregnancies safer through information
Raising community awareness regarding the need for birth spacing, antenatal checkups, proper
nutrition during pregnancy, use of supplements, immunization, use of clean delivery kits at the time
of delivery, and postpartum use of misoprostol must be carried out, especially in rural communities.
In this regard LHWs through their support group meetings can especially raise awareness regarding
use of misoprostol by delivering women.
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ANNEX
Annexure 1. Mobile Network
In case of emergency
Husband /Next of kin
Will call

LHV

Logistics supervisor
Will call
Medical officer of DHQ/THQ
hospital responsible to deal the
emergency

Community person responsible for
provision of transport

Patient shifted to referral facility

Social scientist and inform about the
emergency
Will inform

Supervisor

Will inform

Principal investigator
Note: Separate referral cards were made for intervention & comparison areas and provided in households of
all the recruited women
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Annexure 2: Referral Form
REFERRAL FORM
Referred to:

Serial No:
Name of Patient:
Husband’s Name:
Age:
Address:

REFERRAL INFORMATION

FEEDBACK FROM REFERRAL HEALTH FACILITY(
To be filled by the Doctor Incharge)

( To be filled by LHV)
Diagnosis:
History and Clinical Findings:

Treatment:

Reasons for Referral:

Date:__________________

Signature:__________________

Name:______________________
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Follow‐up:

Date :_________________

Signature:__________________

Name:_______________________

Annexure 3: Pregnant Woman Registration Form
1

S.No: …………….………

2

Registration Date

3

Name:

4

Husband’s Name:

5

Address/Village
( Postal Address )

6

Age (Years)

7

Last Menstrual Period (LMP )

8

Expected Date of Delivery (
EDD )

9

Trimester of Pregnancy

10

Gravida ( No. of pregnancies )

11

Parity ( No. of births after 28
weeks of Pregnancy )

12

No. of Abortions

1 ‐ 3 Months of pregnacy

1

4 ‐ 6 Months of pregnacy

2

7 ‐ 9 Months of pregnacy

3
( If answer is 1 then go to column 14 )

( If answer is none write 00 )
Hemorrhage
pregnancy

13

Past Complications

during
O1

Postpartum Hemorrhage

O2

Cesarean Section

O3

Epilepsy / Fits

O4

Others ( Specify )

77

No Complications

OO
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14

15

16

17

18

Present Complications

Intend to Deliver at Home

Epilepsy / Fits

O5

Hemorrhage during
pregnancy

O6

Hypertension

O7

Multiple pregnancies

O8

Diabetes

O9

Breech / Transverse
presentation

10

Intended Cesarean Section

11

Others ( Specify )

77

No Complications

OO

YES

1

NO

2

Not Confirm

3

YES

1

NO

2

YES

1

NO

2

Eligible Woman

Agreeable to participate in
study after informed consent
Name & Address of Birth
attendant
Issue Date:

19

20
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CDK

Pregnant
Woman
Questionnai
re

Birth
attandant :

Postpartum
Questionnaire
( 24 ‐ 72 hrs )

Return Date :
Next to kin of Pregnant
Woman :

TBA
/
attandant :

Birth

Postpartum Birth attandant
Questionnaire( 24 ‐ 72 hrs )

Postpartum Next to
Kin Questionnaire (
24 ‐ 72 hrs )

Next to kin of Pregnant
Woman :

Postpartum
Questionnaire

Referral

Annexure 4: Serious Adverse Event Report
SERIOUS ADVERSE EVENT REPORT

CBR SERIAL NO: 455

I. EVENT INFORMATION
1.

PATIENT INITIALS

1.a COUNTRY

2. DATE OF BIRTH
Day Month Year

2.a. AGE

2.

SEX

3.a. HEIGHT

3.b. WEIGHT

--

--

years
7.- 13. DESCRIBE EVENT.

√ UNEXPECTED

EXPECTED

Cm
kg
4.-6. EVENT ONSET
Day
Month
Year

DIAGNOSIS:

Description:

8.-12. SERIOUSNESS CRITERIA
CHECK ALL APPROPRIATE
TO EVENT
DEATH (DATE)
Day
Month

Year

HOSPITALIZATION
DISABILITY OR INCAPACITY
LIFE-THREATENING
OTHER SERIOUS CRITERIA
(Cancer, congenital anomaly,
overdose, significant)
NOT APPLICABLE

II. SUSPECT DRUG INFORMATION
14. SUSPECTED DRUG(S) (include generic name(s)

15. DAILY DOSE (include schedule)

16. ROUTE OF ADMINISTRATION

APPLICABLE
21. DID EVENT RE-APPEAR
AFTER REINTRODUCTION?

17. INDICATION(S) FOR USE

18. THERAPY DATES (from/to)
Day

Month

Year

Day

Month

20. DID EVENT ABATE
AFTER STOPPING DRUG?
YES
NO

19. THERAPY DURATION UNTIL REACTION ONSET
Year

YES
NO
NOT APPLICABLE

III. CONCOMITANT DRUGS AND HISTORY
22. CONCOMITANT DRUGS AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

23. OTHER RELEVANT HISTORY (e.g. diseases, allergies, pregnancy etc.)

IV.IND HOLDER INFORMATION

V. INVESTIGATOR’S ASSESSMENT

24.a. NAME AND ADDRESS OF IND HOLDER
Population Council
Center for Biomedical Research
1230 York Avenue
New York, NY 10021 USA
Fax:+1(212)327 86 73
BATCH NO. (when relevant)
24.b. PATIENT IDENTIFIER NO

23.d. OUTCOME

24.c. DATE RECEIVED
Month
Year
Day

24.d. TRIAL NUMBER

24.e. DATE OF THIS REPORT
Day
Month
Year

25.a. REPORT TYPE

Recovered
Recovering
Not Recovered
Sequelae
Fatal
Unknown

23.e. CAUSALITY

Not Related
Unlikely
Possible
Probable
Highly Probable
Insufficient Data

26. NAME AND ADDRESS OF REPORTING PHYSICIAN

INITIAL
FOLLOW-UP
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Annexure 5: Timeline
May Jun July Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug
Activity in Months
UC identification

Selection of Social Scientists

Identification of Birth Attendants & LHVs
Development & Urdu translation of training material & questionnaires
Development of pictorial

Training of Social Scientists, Birth attendants & LHVs

Registration of Eligible pregnant women
Orientation & awareness of women

Supply of Misoprostol to Birth Attendants & EPWs in CDKs
Data collection

Monitoring visits

Data analysis

Report preparation

Dissemination
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Annexure 6: Study Team Members
District Khanewal
Name
Dr.Samreen Afzal

Roles/ Responsibilities
District Supervisor

District Dadu
Name
Dr. Sonia Memon

Roles/ Responsibilities
District Supervisor

Sajida Yasmeen

Social Scientist

Sumaira Anwer

Social Scientist

Naheed Mustafa

Social Scientist

Afroz Channa

Social Scientist

Sadiq Ali

Logistic Supervisor

Najam Uddin Panhwar

Logistic Supervisor

Mumtaz Batool

Social Scientist

Saima Ahmed

Social Scientist

Zainab Amir

Social Scientist

Shams Rehman

Social Scientist

Logistic Supervisor

Rafique Ahmed

Logistic Supervisor

Shahid Ali Tahir
Munaza Iqbal

Social Scientist

Albia Bano

Social Scientist

Samina Mustafa

Social Scientist

Musarat Phanwer

Social Scientist

Logistic Supervisor

Amjad Ali Surhio

Logistic Supervisor

Muh. Mujahid Zia
Sundas Khaliq

Social Scientist

Sumaira Shah

Social Scientist

Shehzadi Nausheen

Social Scientist

Tahira Khanum

Social Scientist

M. Nadeem Hassan

Logistic Supervisor

Saeed Ahmad Memon

Logistic Supervisor
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Annexure 7: Characteristics of Dadu and Khanewal districts
Characteristics
Total Population

Khanewal
2898231

Dadu
1405453

34%

21.0%

27%
40%
73%
37.2%

39.9%
22.6%
64%
33.5%

Contraceptive Prevalence Rate (CPR)
Unmet need for family planning
Literate Women (15-49 Years)
Literate Husband
Overall Literacy Rate

Facilities Providing Maternal Health
Care Services
Reproductive Health Care Providers

Govt.

Public
LHWs

176

1616
339

Private
Govt.

2776
631

Public
LHWs

85

934
218

Private

324
272

Sources:
• http://www.cssforum.com.pk/css‐compulsory‐subjects/pakistan‐affairs/8805‐literacy‐rate‐pakistan‐
district‐wise.html
• Pakistan Population Data Sheet, National Institute of Population Studies (NIPS)
• Baseline Household Survey FALAH, Population Council, Islamabad
• Mapping of Health and reproductive Health Services FALAH, Population Council, Islamabad
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Annexure 8: IBR Approval Letter
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Annexure 9: Maps of Khanewal and Dadu Districts
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Annexure 10: Questionnaires
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